Dreavent

A4Cell is a company focused on developing SPAchip technology, specifically designed for monitoring living single cells. Their offerings include various SPAchips, such as the CytoCHECK SPAchip, which facilitate the real-time study of cellular behavior and processes. A4Cell's devices enable the monitoring of disease progression and allow for individualized assessment of treatment responses. This technology enhances the accuracy and quality of data related to cell studies, ultimately aiming to improve understanding of disease behavior and contribute to advancements in medical research and treatment methodologies.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, is a clinical-stage company focused on developing precision medicines for severe neurological diseases. The company utilizes a functional genomics discovery platform based on human cell lines to identify novel therapeutic targets, addressing the underlying biology of neurodegenerative diseases. By leveraging advancements in neuroscience and human genetics, Nido aims to create precise medications that restore healthy cell function and improve treatment options for conditions that significantly impact patient quality of life.

Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017.

Chimeron Bio Corporation is a Philadelphia-based company established in 2015 that specializes in the discovery and development of personalized immunotherapeutics for cancer treatment. The company focuses on creating self-amplifying therapeutics and vaccines, utilizing a unique platform that employs chimera-encased self-amplifying RNA. This innovative approach allows for superior expression levels and a wider dynamic range compared to traditional messenger RNA technologies. Chimeron Bio aims to provide effective gene therapies and personalized medicine solutions for patients suffering from serious diseases, including cancer, infectious diseases, and genetic disorders.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.